Many strains were successfully isolated by Kangtai biology

In August 4th, twenty-first Century, the economic report reporter learned from Kangtai biology that its research and development project aimed at COVID-19 mutation has made important progress. Many strains of “delta” mutants have been successfully isolated. The following strains will be evaluated strictly according to the quality requirements of the human vaccine, and the vaccine species will be screened, which will lay a good foundation for the large-scale industrialization of the vaccine.

In the early morning, the topic # Shenzhen Kangtai biological successfully isolated delta mutant # rushed to the top of microblog hot search.

In addition, the results of cross neutralization test conducted by Kangtai biology showed that up to now, Kangtai biological new crown inactivated vaccine approved for emergency use can also produce good neutralization response to a variety of new crown variants, and it is still protective.

In addition, on August 4, Sinopharm China biology official micro posted that recently, Sinopharm China biology researcher Yang Xiaoming team recently found an effective monoclonal antibody against delta mutant, with neutralizing activity IC50 as high as 5ng / ml.

In novel coronavirus pneumonia, Delta is a new effective mutant. The new crown mutation therapy is expected to be effective. Related report: heavy! Sinopharm group found a new drug against “delta”! New crown treatment is expected to usher in specific drugs!)

Previously, the person in charge of major domestic new crown vaccine manufacturers such as Sinopharm China biology, Kexing biology and Zhifei biology responded in a media interview on July 29 that their vaccine still has protective effect on Delta and other mutant strains.

It is understood that the characteristics of delta strain mainly include:

1) More infectious. The virulent strain of delta is 50% higher than that of Alfa strain, twice as high as that of the original COVID-19. At the same time, the incubation period and passage interval were shortened, about 1-2 days on average.

2) High viral load may lead to increased disease severity.

3) There may be immune escape, but the existing vaccine still has a protective effect. Among the confirmed cases, the proportion of people who have not been vaccinated into severe or severe cases is significantly higher than that of people vaccinated, and the vaccine still has a protective effect on the new strain.

According to public information, Kangtai biology was established in 1992 and listed on the gem in 2017.

Since its establishment, Kangtai bio is involved in hepatitis B vaccine and other vaccines. Up to now, the products that Kangtai biology has listed and sold include acellular DPT type B Haemophilus influenzae combined vaccine, 23 valent pneumococcal polysaccharide vaccine, recombinant hepatitis B vaccine (Saccharomyces cerevisiae), etc.